Sphingoid compounds for prophylaxis and/or therapy of coronaviridae infection
US11298412B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Sep 24, 2020 |
| Grant date | Apr 12, 2022 |
| Priority date | — |
| Expiry date | Sep 24, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P31/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are processes for the prevention or treatment of infection by SARS-CoV-2. Some aspects provide administration of a sphingoid compound, optionally sphingosine, an active ingredient that activates generation of a sphingoid base, optionally of sphingosine; or an active agent that inhibits the degradation of a sphingoid base, optionally of sphingosine, to a subject such as a human. By increasing the local concentration of sphingosine in a subject or an area of a subject to which the composition is administered such as the airways, nose or interior of the nose or portion thereof, the ability or SARS-CoV-2 to infect the subject or cells thereof is reduced thereby treating of preventing infection by the virus.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.